• 1
    Kallio M,Sankila R,Jaaskelainen J, et al. A population-based study on the incidence and survival rates of 3857 glioma patients diagnosed from 1953 to 1984. Cancer. 1991; 68: 13941400.
  • 2
    Davis FG,Freels S,Grutsch J, et al. Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973–1991. J Neurosurg. 1998; 88: 110.
  • 3
    Curran WJJr,Scott CB,Horton J, et al. Recursive partitioning analysis of prognostic factors in 3 Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst. 1993; 85: 704710.
  • 4
    Lacroix M,Abi-Said D,Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg. 2001; 95: 190198.
  • 5
    Stupp R,Mason WP,van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352: 987996.
  • 6
    Burger PC,Dubois PJ,Schold SCJr, et al. Computerized tomographic and pathologic studies of the untreated, quiescent, and recurrent glioblastoma multiforme. J Neurosurg. 1983; 58: 159169.
  • 7
    Giese A,Bjerkvig R,Berens ME,Westphal M. Cost of migration: invasion of malignant gliomas and implications for treatment. J Clin Oncol. 2003; 21: 16241636.
  • 8
    Hoelzinger DB,Mariani L,Weis J, et al. Gene expression profile of glioblastoma multiforme invasive phenotype points to new therapeutic targets. Neoplasia. 2005; 7: 716.
  • 9
    Di Costanzo A,Trojsi F,Giannatempo GM, et al. Spectroscopic, diffusion and perfusion magnetic resonance imaging at 3.0 Tesla in the delineation of glioblastomas: preliminary results. J Exp Clin Cancer Res. 2006; 25: 383390.
  • 10
    Mangiola A,Lama G,Giannitelli C, et al. Stem cell marker Nestin and c-Jun NH2-terminal kinases in tumor and peritumor areas of glioblastoma multiforme: possible prognostic implications. Clin Cancer Res. 2007; 13: 69706977.
  • 11
    Shinoda J,Sakai N,Murase S, et al. Selection of eligible patients with supratentorial glioblastoma multiforme for gross total resection. J Neurooncol. 2001; 52: 161171.
  • 12
    Sawaya R,Hammoud M,Schoppa D, et al. Neurosurgical outcomes in a modern series of 400 craniotomies for treatment of parenchymal tumors. Neurosurgery. 1998; 42: 10441056.
  • 13
    Wigner MJ,MacDonald DR,Cairncross JG. Supratentorial anaplastic gliomas in adults: the prognostic importance of extent of resection and prior low-grade glioma. J Neurosurg. 1989; 71: 487493.
  • 14
    Simpson JR,Horton J,Scott C, et al. Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of 3 consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. Int J Radiat Oncol Biol Phys. 1993; 26: 239244.
  • 15
    Sneed PK,Prados MD,McDermott MW, et al. Large effect of age on survival of patients with glioblastoma treated with radiotherapy and brachytherapy boost. Neurosurgery. 1995; 36: 898903.
  • 16
    Salminen E,Nuutinen JM,Huhtala S. Multivariate analysis of prognostic factors in 106 patients with malignant glioma. Eur J Cancer. 1996; 32: 19181923.
  • 17
    Kowalczuk A,MacDonald RL,Amidei C, et al. Quantitative imaging study of extent of surgical resection and prognosis of malignant astrocytomas. Neurosurgery. 1997; 41: 10281036.
  • 18
    Silbergeld DL,Chicoine MR. Isolation and characterization of human malignant glioma cells from histologically normal brain. J Neurosurg. 1997; 86: 525531.
  • 19
    Schiffer D,Cavalla P,Dutto A,Borsotti L. Cell proliferation and invasion in malignant glioma. Anticancer Res. 1997; 17: 6169.
  • 20
    Dalrymple SJ,Parisi JE,Roche PC, et al. Changes in proliferating cell nuclear antigen expression in glioblastoma multiforme cells along a stereotactic biopsy trajectory. Neurosurgery. 1994; 35: 10361044.
  • 21
    Berens ME,Giese A. “… Those left behind.” Biology and oncology of invasive glioma cells. Neoplasia. 1999; 1: 208219.